64 studies found for:    cabozantinib
Show Display Options
Rank Status Study
1 Recruiting Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 (16 Years +)
Conditions: NF1;   Neurofibromatosis;   Plexiform Neurofibromas
Intervention: Drug: Cabozantinib
2 Recruiting Cabozantinib and Panitumumab to Treat KRAS Wild-Type Metastatic Colorectal Cancer
Condition: Colorectal Cancer
Interventions: Biological: Panitumumab;   Drug: Cabozantinib
3 Recruiting Cabozantinib for Malignant Pheochromocytoma
Condition: Neuroendocrine Tumors
Interventions: Drug: Cabozantinib;   Behavioral: Questionnaire
4 Recruiting A Phase II Study of Cabozantinib (XL184) Therapy in Castrate Resistant Prostate Cancer (CRPC) With Visceral Metastases
Condition: Prostate Cancer
Intervention: Drug: Cabozantinib
5 Active, not recruiting A Phase II Study of Cabozantinib (XL-184) Monotherapy in Patients With Advanced Cholangiocarcinoma After Progression on First or Second Line Systemic Therapy
Conditions: Bile Duct Cancer;   Intrahepatic Cholangiocarcinoma;   Cholangiocarcinoma of the Extrahepatic Bile Duct
Intervention: Drug: Cabozantinib
6 Active, not recruiting Trial of Cabozantinib (XL184) in Castrate-Resistant Prostate Cancer Metastatic to Bone
Condition: Prostate Cancer Metastatic
Intervention: Drug: Cabozantinib
7 Active, not recruiting Cabozantinib in Treating Younger Patients With Recurrent or Refractory Solid Tumors
Conditions: Childhood Solid Neoplasm;   Recurrent Melanoma;   Recurrent Thyroid Gland Carcinoma;   Thyroid Gland Medullary Carcinoma
Interventions: Drug: Cabozantinib S-malate;   Other: Pharmacological Study;   Other: Laboratory Biomarker Analysis
8 Active, not recruiting Dose-Finding Study of Cabozantinib (XL184) in Japanese Subjects With Advanced Cancer
Conditions: Solid Tumors;   Cancer;   NSCLC
Interventions: Drug: cabozantinib capsules;   Drug: cabozantinib tablets
9 Recruiting Cabozantinib-S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency Virus
Conditions: Adult Solid Neoplasm;   HIV Infection
Interventions: Drug: Cabozantinib S-malate;   Other: Pharmacological Study;   Other: Laboratory Biomarker Analysis
10 Recruiting Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer
Conditions: Poorly Differentiated Thyroid Gland Carcinoma;   Recurrent Thyroid Gland Carcinoma;   Stage I Thyroid Gland Follicular Carcinoma;   Stage I Thyroid Gland Papillary Carcinoma;   Stage II Thyroid Gland Follicular Carcinoma;   Stage II Thyroid Gland Papillary Carcinoma;   Stage III Thyroid Gland Follicular Carcinoma;   Stage III Thyroid Gland Papillary Carcinoma;   Stage IVA Thyroid Gland Follicular Carcinoma;   Stage IVA Thyroid Gland Papillary Carcinoma;   Stage IVB Thyroid Gland Follicular Carcinoma;   Stage IVB Thyroid Gland Papillary Carcinoma;   Stage IVC Thyroid Gland Follicular Carcinoma;   Stage IVC Thyroid Gland Papillary Carcinoma
Interventions: Drug: Cabozantinib S-malate;   Other: Laboratory Biomarker Analysis
11 Recruiting Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: Cabozantinib;   Drug: Androgen Ablation Therapy
12 Recruiting Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma
Conditions: Merkel Cell Carcinoma;   Skin Cancer
Intervention: Drug: Cabozantinib
13 Suspended Cabozantinib in Advanced Solid Malignancies
Conditions: Lung Cancer;   Solid Tumor (Not Breast or Prostate Cancers)
Intervention: Drug: Cabozantinib
14 Terminated Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery
Conditions: Recurrent Melanoma;   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: cabozantinib-s-malate;   Drug: vemurafenib;   Other: laboratory biomarker analysis;   Other: pharmacological study
15 Active, not recruiting Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or In Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer
Conditions: Recurrent Non-Small Cell Lung Carcinoma;   Stage IV Non-Small Cell Lung Cancer
Interventions: Drug: Erlotinib Hydrochloride;   Drug: Cabozantinib S-malate;   Other: Laboratory Biomarker Analysis
16 Recruiting Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
Condition: Non-Small Cell Lung Cancer
Intervention: Drug: Cabozantinib
17 Recruiting Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib
Condition: Hepatocellular Carcinoma
Interventions: Drug: Cabozantinib (XL184);   Drug: Placebo
18 Recruiting A Trial of Cabozantinib (XL184) and Gemcitabine in Advanced Pancreatic Cancer
Condition: Pancreatic Cancer
Interventions: Drug: CABOZANTINIB;   Drug: gemcitabine
19 Recruiting Cabozantinib in Treating Men With Castration-Resistant Prostate Cancer
Conditions: Adenocarcinoma of the Prostate;   Castration-resistant Prostate Cancer;   Recurrent Prostate Cancer;   Stage III Prostate Cancer;   Stage IV Prostate Cancer
Interventions: Drug: cabozantinib-s-malate;   Other: laboratory biomarker analysis
20 Recruiting Cabozantinib-S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer
Conditions: Endometrial Adenosquamous Carcinoma;   Endometrial Clear Cell Adenocarcinoma;   Endometrial Mixed Adenocarcinoma;   Endometrial Serous Adenocarcinoma;   Recurrent Uterine Corpus Carcinoma;   Stage IVA Uterine Corpus Cancer;   Stage IVB Uterine Corpus Cancer
Interventions: Drug: Cabozantinib S-malate;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years